Pardes Biosciences, Inc. Common Stock
PRDS
PRDS was delisted on the 30th of August, 2023.
61 hedge funds and large institutions have $176M invested in Pardes Biosciences, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 15 reducing their positions, and 13 closing their positions.
5% more capital inflows, than outflows
Capital inflows: $19.7M | Capital outflows: $18.7M
0.52% more ownership
Funds ownership: 84.62% → 85.14% (+0.52%)
12% less funds holding
Funds holding: 69 → 61 (-8)
62% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 13
73% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 15
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$9.6M |
| 2 |
Arena Capital Advisors
Los Angeles,
California
|
+$5.29M |
| 3 |
EcoR1 Capital
San Francisco,
California
|
+$2.2M |
| 4 |
Omni Partners US
Irvine,
California
|
+$2M |
| 5 |
Woodline Partners
San Francisco,
California
|
+$309K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marathon Asset Management (New York)
New York
|
-$5.79M |
| 2 |
Glazer Capital LLC
New York
|
-$1.92M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.66M |
| 4 |
Sage Rock Capital Management
New York
|
-$1.59M |
| 5 |
C
Chescapmanager
Baltimore,
Maryland
|
-$1.38M |
PRDS Hedge Fund Activity: Q3 2021 in Review
61 of the 5,731 institutional investors tracked by Wall St. Rank reported a position in Pardes Biosciences, Inc. Common Stock (PRDS) for Q3 2021, worth a combined $176M — up 0.25% from $175M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of PRDS and 5 opened new positions — a net loss of 8 holders — while 15 trimmed existing stakes and 4 added.
The largest buyer was Platinum Investment Management, opening a new position worth an estimated $9.6M. The largest seller was Marathon Asset Management (New York), exiting entirely with an estimated $5.79M sold.
- 61 institutional investors held Pardes Biosciences, Inc. Common Stock (PRDS) as of Q3 2021, down from 69 in Q2 2021.
- Funds reported $176M of Pardes Biosciences, Inc. Common Stock stock for Q3 2021, up 0.25% quarter-over-quarter.
- 5 funds opened new Pardes Biosciences, Inc. Common Stock positions in Q3 2021 and 13 closed out, a net change of -8 holders.
- The largest Pardes Biosciences, Inc. Common Stock buyer in Q3 2021 was Platinum Investment Management, an estimated $9.6M added.
- The largest Pardes Biosciences, Inc. Common Stock seller in Q3 2021 was Marathon Asset Management (New York), an estimated $5.79M sold.
Based on aggregated 13F filings for Q3 2021.